The European Medicines Agency (EMA) has published a document titled "Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (27 March 2026 - 23 April 2026)", dated 19 May 2026. The document lists type II variation procedures for extension of indication that were under evaluation by the Committee for Medicinal Products for Human Use (CHMP) during the period from 27 March to 23 April 2026. Type II variations are significant changes to a marketing authorisation, such as adding a new therapeutic indication or modifying an existing one. The publication provides transparency on which medicines are undergoing regulatory review for expanded use, impacting pharmaceutical companies, healthcare providers, and patients awaiting new treatment options. The document does not include outcomes or decisions, only the initiation of evaluation procedures. No prior coverage of this specific document exists in the public record.
← Atlas › News › Health & Lifestyle